会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
    • 治疗阿尔茨海默氏病的方法包括将去铁胺(DFO)施用于鼻腔上三分之一
    • US07776312B2
    • 2010-08-17
    • US11580366
    • 2006-10-13
    • William H. Frey, IISamuel Scott PanterLeah Ranae Bresin HansonAnnina Roeytenberg
    • William H. Frey, IISamuel Scott PanterLeah Ranae Bresin HansonAnnina Roeytenberg
    • A61K49/00A01K31/00A01K9/00
    • A61K9/0043A61K31/165A61K31/195A61K38/1841A61K38/2006A61K38/28A61K38/30A61K45/06A61K2800/522
    • Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.
    • 用于预处理和/或向动物中枢神经系统提供神经保护作用的方法和/或药物组合物抵抗涉及缺血,创伤,金属中毒和神经变性的神经障碍的影响,包括相关的认知,行为和身体损伤。 在一个实施方案中,该方法通过刺激和/或稳定缺氧诱导因子-1α(HIF-1α)来实现。 已知HIF-1α在缺血条件下提供神经保护作用。 在另一个实施方案中,该方法通过差异性降低,抑制或预防由神经障碍引起的所选基因的表达增加来实现。 与某些与脑缺血风险有关的疾病或病症有风险的患者可能会受益,例如阿尔茨海默病,帕金森病,威尔逊氏症,亨廷顿舞蹈病,地中海贫血或中风危险的患者,或患有头部或脊髓损伤的患者 。 患有可能导致缺血的某些医疗程序的患者也可能受益。 最初认识到缺血或神经变性的可能性。 将鼻内治疗剂施用于鼻腔的上三分之一以绕过血脑屏障,并直接进入中枢神经系统,以避免不必要的和可能致命的副作用。 治疗剂包括与铁和/或铜相互作用的那些物质,例如铁螯合剂,铜螯合剂和抗氧化剂。 这些治疗剂的具体实例是铁螯合剂去铁胺(DFO)和去铁素。 已知DFO的鼻内给药可以刺激和/或稳定HIF-1α,并提供了一种预防大脑预防脑缺血的有效和安全的方法。
    • 9. 发明申请
    • MediaDescription data structures for carrying descriptive content metadata and content acquisition data in multimedia systems
    • 媒体描述数据结构,用于在多媒体系统中传送描述性内容元数据和内容获取数据
    • US20060167903A1
    • 2006-07-27
    • US11042480
    • 2005-01-25
    • Geoffrey SmithKevin CarleMichael CleronSamuel ScottVictor Lee
    • Geoffrey SmithKevin CarleMichael CleronSamuel ScottVictor Lee
    • G06F17/30
    • G06F17/30817H04L65/602H04L67/28H04L67/2842
    • A MediaDescription data structure that includes both descriptive metadata, such as EPG information, about a multimedia content item and instructions for acquiring the content item is assigned to each multimedia content item in a multimedia system. A MediaDescription data structure is transferable as a token for representing the content item. The acquisition information may also include information about presenting the content item in different view contexts, as well as information about relationships to other pieces of content, and information about how each different version of the content item is to be acquired and displayed. MediaDescription data structure tokens can be used to facilitate digital video recording (DVR) processes, Internet content rendering processes, multimedia search processes, search results aggregating processes, video-on-demand (VOD) processes, pay-per-view processes, and program guide rendering processes.
    • 包括关于多媒体内容项目的诸如EPG信息的描述性元数据和用于获取内容项目的指令的MediaDescription数据结构被分配给多媒体系统中的每个多媒体内容项目。 MediaDescription数据结构可作为用于表示内容项的令牌转移。 获取信息还可以包括关于在不同视图环境中呈现内容项目的信息,以及关于与其他内容片段的关系的信息,以及关于如何获取和显示内容项目的每个不同版本的信息。 媒体描述数据结构令牌可用于促进数字视频录制(DVR)过程,互联网内容呈现过程,多媒体搜索过程,搜索结果聚合过程,视频点播(VOD)流程,按次付费流程和程序 指导渲染过程。